Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis

By Michael Detmar, Lawrence F. Brown, Kevin P. Claffey, Kiang-Teck Yeo, Olivier Kocher, Robert W. Jackman, Brygida Berse, and Harold F. Dvorak

From the Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215

Summary

Psoriatic skin is characterized by microvascular hyperpermeability and angioproliferation, but the mechanisms responsible are unknown. We report here that the hyperplastic epidermis of psoriatic skin expresses strikingly increased amounts of vascular permeability factor (VPF; vascular endothelial growth factor), a selective endothelial cell mitogen that enhances microvascular permeability. Moreover, two VPF receptors, kdr and fli-1, are overexpressed by papillary dermal microvascular endothelial cells. Transforming growth factor α (TGF-α), a cytokine that is also overexpressed in psoriatic epidermis, induced VPF gene expression by cultured epidermal keratinocytes. VPF secreted by TGF-α-stimulated keratinocytes was bioactive, as demonstrated by its mitogenic effect on dermal microvascular endothelial cells in vitro. Together, these findings suggest that TGF-α regulates VPF expression in psoriasis by an autocrine mechanism, leading to vascular hyperpermeability and angiogenesis. Similar mechanisms may operate in tumors and in healing skin wounds which also commonly express both VPF and TGF-α.

Materials and Methods

In Situ Hybridization and Immunohistochemistry. 6-mm punch biopsies were taken, after obtaining informed consent, from the involved and uninvolved skin of six patients with chronic plaque-type psoriasis that had not been treated for a period of at least 6 wk and from the normal skin of six healthy volunteers. In situ hybridization was performed on 6 μm fresh-frozen tissue sections using single-stranded antisense or control sense riboprobes as described. The VPF probe was prepared from a 204-bp VPF cDNA fragment isolated from human HT 1080 cells. Riboprobes for the VPF receptors, kdr and flt-1, were prepared from cDNA fragments.
as described (21). Immunohistochemistry was performed on fresh-frozen tissue sections reacted with an affinity-purified rabbit antibody against a 26-amino acid peptide corresponding to the NH2-terminus of human VPF as described (31). The specificity of this antibody has been documented by Western blotting (32). As a negative control, primary anti-VPF antibody was replaced with an equivalent concentration of normal rabbit IgG.

Cell Culture. Human epidermal keratinocyte cultures were established from normal adult body skin of healthy volunteers and propagated in serum-free keratinocyte growth medium (KGM) (Clonetics Corp., San Diego, CA) as described (33). Second passage keratinocytes were used in all experiments. Human dermal microvascular endothelial cells (HDMEC) were isolated from neonatal foreskins after routine circumcisions as described (34) and cultured on fibronectin-coated culture dishes in endothelial basal (EBM) (Clonetics Corp.), supplemented with 20% FCS, 1 μg/ml hydrocortisone acetate, and 10 μM dibutyryl-cAMP (all from Sigma Chemical Co., St. Louis, MO).

Northern Blot Analysis. Total cellular RNA was extracted from confluent, second-passage keratinocytes cultured in 100-mm dishes for 24 h in KBM without added growth factors, with 0.1-100 ng/ml recombinant human TGF-α (British Biotechnology, Abington, UK) or with 10 ng/ml recombinant human epidermal growth factor (EGF; Clonetics Corp.) as described (35). Northern blots were hybridized with a human VPF cDNA probe (546 bp) obtained by reverse transcription-PCR of RNA from human glioblastoma U-373 cells, using the oligonucleotide primers 5'-TCCGAATTCGCA-3' and 5'-TTCGAATTCCTGAGGA-GCTCC-3'. Control hybridization was performed with ribosomal-associated protein cDNA, 36B4 (36) to demonstrate equivalent RNA loading.

VPF Immunofluorometric Assay. Confluent second passage keratinocytes were cultured in 24-well plates for 48 h in KBM without added growth factors, or with added TGF-α (0.1-100 ng/ml), or with TGF-α (100 ng/ml) plus 10 μg/ml rabbit anti-EGF receptor antibody (UBI, Lake Placid, NY). VPF was quantitated in conditioned media (CM) by a modified two-site, time-resolved immunofluorometric assay (37) using a polyclonal antibody against recombinant human VPF for both capture and detection. Values were normalized for total cell numbers after culture. Data are expressed as pM VPF/10^6 cells. In these and other experiments, statistical significance was calculated with the Dunnett multiple comparison test.

Bioassay for Mitogenic Activity of Keratinocyte CM. CM was collected from confluent keratinocyte cultures in 100-mm dishes for 48 h in 5 ml KBM medium supplemented with 100 ng/ml TGF-α and stored frozen at -80°C for up to 2 wk. As control, medium was added to culture dishes without cells and incubated and processed identically. Second passage HDMEC were seeded at 5 × 10^3 cells/cm² in 24-well plates in EBM medium supplemented with 2% FCS. After 16 h, varying amounts (1-30%) of keratinocyte conditioned or control medium were added to quadruplicate wells for 48 h. 1 μCi/ml methyl-[^3]H]thymidine (sp act 82.4 Ci/mmol; DuPont NEN, Boston, MA) was added during the final 6 h of culture, and the thymidine incorporation into DNA was determined as described (38). Data are expressed as a stimulatory index: ratio of net [^3]H]thymidine incorporation by HDMEC cultured with conditioned or control medium.

VPF Depletion by Solid Phase Immunoadsorption. CM from keratinocyte cultures treated with 100 ng/ml TGF-α (see above) were depleted of VPF by solid phase immunoadsorption as described (32), using the same affinity-purified anti-VPF antibody as for immunohistochemistry, coupled to protein A-Sepharose beads (Pharmacia, Uppsala, Sweden). As a control, CM was depleted of TGF-α with a specific polyclonal antibody (Peprotech, Rocky Hill, NJ) or incubated with Sepharose beads alone. Control medium was treated identically. The capacity of these CM to stimulate HDMEC thymidine incorporation was measured as described above.

Results and Discussion

Initial experiments were performed to determine whether VPF was overexpressed in psoriatic skin. In situ hybridization (ISH) demonstrated enhanced expression of VPF mRNA in the hyperplastic epidermis of all psoriatic patients biopsied (Fig. 1 A). As in healing skin wounds, differentiated keratinocytes of the suprabasal layers labeled most intensely, but VPF mRNA was also expressed focally by basal keratinocytes and by rare mononuclear inflammatory cells infiltrating the upper dermis. In contrast, little or no VPF mRNA was expressed in the epidermis of all normal volunteers (Fig. 1 C). ISH performed on areas of skin from psoriatic patients that appeared clinically normal also revealed focally increased expression of VPF mRNA. However, these biopsies also showed microscopic abnormalities suggestive of early psoriatic activity. Consistent with these ISH findings, immunohistochemistry of clinically involved psoriatic skin revealed strong cytoplasmic staining for VPF, predominantly in suprabasal epidermal keratinocytes (Fig. 1 E). ISH was also employed to identify sites of VPF receptor mRNA expression. Strong labeling for the mRNAs of both kdr and Flt-1 was observed in the papillary dermal microvessels of active psoriatic lesions (Fig. 1 D). In contrast, little or no receptor expression was detected in deeper vessels of psoriatic skin or in vessels of normal skin.

Because increased VPF expression likely contributes to the microvascular hyperpermeability and angiogenesis of tumors and healing skin wounds (14-17), we reasoned that a common mediator might be responsible for upregulating VPF expression in these disorders as well as in psoriasis. A likely candidate was TGF-α, a cytokine with angiogenic properties in vivo (39) and one known to be overexpressed in the epidermis of psoriatic skin lesions and of healing skin wounds and in many epithelial tumors (28, 29, 40).

To test the possibility that TGF-α might regulate VPF expression in psoriasis, we performed Northern analyses on RNA extracted from confluent human epidermal keratinocytes, cultured with or without TGF-α. VPF mRNA expression was upregulated by TGF-α in a dose-dependent fashion at concentrations ≥1 ng/ml (Fig. 2 A). EGF also upregulated VPF mRNA expression by cultured keratinocytes (Fig. 2 A); TGF-α is structurally related to EGF and reacts with the EGF receptor (41, 42).

To determine whether TGF-α also increased synthesis and secretion of VPF protein, we tested keratinocyte CM for VPF by immunoassay. After 48 h of culture in the presence of TGF-α, keratinocyte CM contained significantly increased amounts of immunoreactive VPF protein. At 100 ng/ml, TGF-α increased VPF levels fivefold, and a statistically significant increase was noted with concentrations as low as 3 ng/ml (Fig. 2 B). This effect was mediated by TGF-α binding to the EGF receptor, since addition of an anti-EGF receptor
Figure 1. Localization of VPF and VPF receptors in histological sections of psoriatic and normal skin by ISH (A–D) and immunohistochemistry (E and F). (A) Hyperplastic epidermis of psoriatic skin hybridized with a specific 35S-antisense riboprobe that recognizes all VPF isoforms. Note intense labeling of keratinocytes, especially in the suprabasal layers. (B) Control hybridization with VPF sense riboprobe on an adjacent section shows low background. (C) Low level VPF mRNA expression by scattered keratinocytes in normal skin hybridized with VPF antisense probe. (D) Selective labeling of microvessels in the papillary dermis of psoriatic skin (arrows) with antisense probe specific for the VPF receptor kdr. Identical labeling (not illustrated) was observed with antisense riboprobe to a second VPF endothelial cell receptor, flt-1. (E) Immunohistochemical localization of VPF protein in the epidermis of lesional psoriatic skin. Note prominent cytoplasmic staining of keratinocytes in the suprabasal layers. (F) Negative immunoperoxidase control in which primary anti-VPF antibody was replaced with normal rabbit IgG. (A–F): ×430.

Figure 2. Dose-dependent increase of VPF mRNA (A) and protein (B) in human keratinocytes cultured with or without TGF-α or EGF. (A) Northern blot of total RNA (20 µg/lane) extracted from confluent keratinocytes cultured for 4 h in KBM medium without added growth factors (C), with varying concentrations of TGF-α, or with 10 ng/ml EGF. The blot was hybridized with a VPF cDNA probe; control hybridization with ribosome-associated protein cDNA, 36B4 demonstrates equivalent RNA loading. (B) VPF protein in the CM of keratinocytes cultured for 48 h in KBM medium alone (○), or supplemented with TGF-α (0.1–100 ng/ml, ●), or supplemented with 100 ng/ml TGF-α plus 10 µg/ml rabbit anti-EGF receptor antibody (△). Data are expressed as pM VPF per 10^5 cells (mean ± SD; n = 3); p < 0.05 for 3 ng/ml, p <0.01 for 10–100 ng/ml.

1143 Detmar et al. Brief Definitive Report
antibody inhibited VPF induction by TGF-α (Fig. 2 B). Though somewhat less effective, EGF also increased the amount of VPF released by cultured keratinocyte (data not shown). Inasmuch as TGF-α and EGF receptors (but not EGF itself) are overexpressed in psoriatic skin (28, 29, 43), our findings suggest that TGF-α may stimulate VPF synthesis and secretion by epidermal keratinocytes in psoriasis. This is further supported by the almost identical localization of keratinocytes expressing VPF mRNA and TGF-α mRNA (44) within the epidermis. In contrast, neither IL-6 nor -8, other cytokines increased in lesional psoriatic epidermis, modulated VPF levels in keratinocyte CM.

The VPF identified in keratinocyte CM by immunoassay was biologically active, as measured by its capacity to stimulate thymidine incorporation in cultured HDMEC. HDMEC strongly express VPF receptors and proliferate in response to graded doses of VPF (Detmar, M., unpublished data). CM obtained from TGF-α-treated keratinocyte cultures was potently mitogenic for HDMEC in a concentration-dependent fashion (Fig. 3 A). Because the mitogenic effect of keratinocyte CM might have resulted from secreted products other than VPF, possibly including TGF-α itself, additional experiments were performed to demonstrate specificity. Depletion of VPF by specific antibodies removed more than 80% of the endothelial cell mitogenic activity present in CM derived from TGF-α-treated keratinocyte cultures. In contrast, depleting CM of TGF-α was without effect (Fig. 3 B).

Our findings indicate that both VPF and two of its receptors are strikingly overexpressed in psoriatic skin and, by this mechanism, likely induce the increased numbers of hyperpermeable blood vessels required to meet the increased nutritional needs of the hyperplastic psoriatic epidermis. It remains to be established whether additional angiogenic factors also contribute to the microvascular alterations in psoriasis. Whereas production of platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) by epidermal keratinocytes in vitro, as well as increased expression of PDGF receptors by dermal psoriatic vessels, have been previously demonstrated (45, 46), elevated levels of these factors in psoriatic skin have not been reported. Moreover, neither PDGF nor bFGF is known to increase microvascular permeability.

Our in vitro findings indicate that TGF-α potently upregulates VPF expression in epidermal keratinocytes. Because TGF-α and the EGF receptor with which it interacts are also upregulated in psoriatic epidermis (28, 29, 43), it is likely that TGF-α, in addition to its mitogenic effect on epidermal keratinocytes, upregulates VPF expression in psoriasis by an autocrine mechanism. These findings have potential significance for, in addition to psoriasis, the pathogenesis of the vascular hyperpermeability and angiogenesis that characterize many tumors and healing wounds, conditions in which VPF, TGF-α, and their receptors are also overexpressed (14–20, 40, 43).

---

We thank S. J. Galli, D. R. Senger, and W. H. Clark for helpful discussions and critical review of this manuscript; E. J. Manseau, K. Tognazzi, and T.-K. Yeo for technical assistance; S. M. Ollbricht for providing skin samples; and L. C. Plantefer for providing epidermal keratinocyte cultures.

This work was supported by Deutsche Forschungsgemeinschaft grant De 483/3-1, by National Institutes of Health/National Cancer Institute grants CA-50453 and CA-58845, and by the BIH Pathology Foundation, Inc.
References

1. Weinstein G.D., J.L. McCullough, and P.A. Ross. 1985. Cell kinetic basis for pathophysiology of psoriasis. J. Invest. Dermatol. 85:579.

2. Fry L. 1984. Psoriasis. Br. J. Dermatol. 119:445.

3. Christophers E., R. Parzefall, and O. Braun-Falco. 1973. Initial events in psoriasis: quantitative assessment. Br. J. Dermatol. 89:327.

4. Ryan T.J. 1980. Microcirculation in psoriasis. Pharmacol. & Ther. (B), 10:27.

5. Braverman I.M., and A. Keh-Yen. 1986. Three-dimensional reconstruction of endothelial cell gaps in psoriatic vessels and their morphologic identity with gaps produced by the intradermal injection of histamine. J. Invest. Dermatol. 86:577.

6. Bull R.H., D.O. Bates, and P.S. Mortimer. 1992. Intravital video-capillaroscopy for the study of microcirculation in psoriasis. Br. J. Dermatol. 126:436.

7. Braverman I.M., and J. Sibley. 1982. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J. Invest. Dermatol. 78:12.

8. Jungkunz W., M. Eichhorn, J. Wurl, W.C. Marsch, and H. Holzmann. 1992. Carbonic anhydrase—a marker for fenestrated capillaries in psoriasis. Arch. Dermatol. Res. 284:146.

9. Pinkus H., and A.H. Mehregan. 1966. The primary histologic lesion of seborrhoeic dermatitis and psoriasis. J. Invest. Dermatol. 46:109.

10. Brody l. 1984. Dermal and epidermal involvement in the evolution of acute eruptive guttate psoriasis vulgaris. J. Invest. Dermatol. 82:465.

11. Schubert C., and E. Christophers. 1985. Mast cells and macrophages in early relapsing psoriasis. Arch. Dermatol. Res. 277:352.

12. Parent D., B.A. Bernard, C. Desbas, M. Heenen, and M.Y. Durand. 1990. Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology. J. Invest. Dermatol. 95:333.

13. Malhotra R., K.S. Stern, L.A. Fernandez, and I.M. Braverman. 1989. The angiogenic properties of normal and psoriatic skin associate with the epidermis—not the dermis. Lab Invest. 61:162.

14. Dvorak H.F., N.S. Orenstein, A.C. Carvalho, W.H. Churchill, A.M. Dvorak, S.J. Galli, J. Feder, A.M. Bitzer, J. Rypstyc, and P. Giovincio. 1979. Induction of a fibrin-gel invesment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122:166.

15. Senger D.R., S.J. Galli, A.M. Dvorak, C.A. Peruzzi, V.S. Harvey, and H.F. Dvorak. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Wash. DC). 219:983.

16. Senger D.R., L. Van De Water, L. Brown, J. Nagy, K.-T. Yeo, T.-K. Yeo, B. Berse, R. Jackman, A. Dvorak, and H.F. Dvorak. 1993. Vascular permeability factor (VPF, VEGF) in tumour biology. Cancer Metastasis Rev. 12:303.

17. Berkman R.A., M.J. Merrill, W.C. Reinhold, W.T. Monacci, A. Saxena, W.C. Clark, J.T. Robertson, I.U. Ali, and E.H. Oldfield. 1993. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91:153.

18. Brown L.F., K.-T. Yeo, B. Berse, T.-K. Yeo, D.R. Senger, H.F. Dvorak, and L. Van De Water. 1992. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176:1375.

19. Plate H., G. Breier, H.A. Weich, and W. Risau. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond.). 359:845.

20. Brown L.F., B. Berse, R.W. Jackman, K. Tognazzi, E.J. Manseau, D.R. Senger, and H.F. Dvorak. 1993. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53:4727.

21. Brown L.F., B. Berse, R.W. Jackman, K. Tognazzi, E.J. Manseau, H.F. Dvorak, and D.R. Senger. 1993. Vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143:1255.

22. Senger D.R., C.A. Perruzzi, J. Feder, and H.F. Dvorak. 1986. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46:5629.

23. Keck P.J., S.D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder, D.T. Connolly. 1989. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Wash. DC). 246:1309.

24. Leung D.W., G. Cachianes, W.-J. Kuang, D.V. Goeddel, and N. Ferrara. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Wash. DC). 246:1309.

25. Connolly D.T., D.M. Heuselrn, R. Nelson, J.V. Olander, B.L. Eppley, J.J. Delfino, N.R. Siegel, R.M. Leimgruber, and J. Feder. 1989. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84:1470.

26. Ferrara N., and W.J. Hengel. 1989. Pituitary follicular cells secrete a novel heparin-biding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:851.

27. Gospodarowicz D.J., J.A. Abraham, and J. Schilling. 1989. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc. Natl. Acad. Science USA. 86:7311.

28. Gottlieb A.B., C.K. Chang, D.N. Posnett, B. Fanelli, and J.P. Tam. 1988. Detection of transforming growth factor α in normal, malignant, and hyperproliferative human keratinocytes. J. Exp. Med. 167:670.

29. Elder J.T., G.T. Fisher, P.B. Lindquist, G.L. Bennett, M.R. Pinteklow, R.J. Coffey, L. Ellingsworth, R. Derynick, and J.J. Voorhees. 1989. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (Wash. DC). 243:811.

30. Berse B., L.F. Brown, L. Van De Water, H.F. Dvorak, and D.R. Senger. 1992. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell. 3:211.

31. Dvorak H.F., T.M. Sioussat, L.F. Brown, B. Berse, J.A. Nagy, A. Sotrel, E.J. Manseau, L. Van de Water, and D.R. Senger. 1991. Distribution of vascular permeability factor (vascular en-
dothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp Med. 174:1275.
32. Sioussat T.M., H.F. Dvorak, T.A. Brock, and D.R. Senger. 1993. Inhibition of vascular permeability factor (vascular endothelial growth factor) with anti-peptide antibodies. Arch. Biochem. Biophys. 301:15.
33. Detmar M., and C.E. Orfanos. 1990. Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro. Arch. Dermatol. Res. 282:238.
34. Detmar M., S. Tenorio, U. Hettmannsperger, Zb. Ruszczak, and C.E. Orfanos. 1992. Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. J. Invest. Dermatol. 98:147.
35. Claffey K.P., W.O. Wilkinson, and B.M. Spiegelman. 1992. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J. Biol. Chem. 267:16137.
36. Masiakowski P., R. Breathnach, J. Bloch, F. Gannon, A. Krust, and P. Chambon. 1982. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10:7895.
37. Yeo K.-T., H.H. Wang, J.A. Nagy, T.M. Sioussat, S.R. Leedbetter, A.J. Hoogewerf, Y. Zhou, E.M. Masse, D.R. Senger, and H.F. Dvorak. 1993. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory infusions. Cancer Res. 53:2912.
38. Detmar M., A. Mayer-da-Silva, R. Stadler, and C.E. Orfanos. 1989. Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J. Invest. Dermatol. 93:70.
39. Schreiber A., M.E. Winkler, and R. Derynck. 1986. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science (Wash. DC). 232:1250.
40. Derynck R., D.V. Goeddel, A. Ullrich, J.U. Gutterman, R.D. Williams, T.S. Bringman, and W.H. Berger. 1987. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 47:707.
41. Massagué J. 1983. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptor in human placenta membranes and A 431 cells. J. Biol. Chem. 258:13614.
42. Marquardt H., M.W. Hunkapiller, L.E. Hood, and J. Todaro. 1984. Rat transforming growth factor type I: structure and relation to epidermal growth factor. Science (Wash. DC). 223:1079.
43. Nanney C.B., C.M. Stoschek, M. Magid, and L.E. King. 1986. Altered 125I-epidermal growth factor binding and receptor distribution in psoriasis. J. Invest. Dermatol. 86:260.
44. Schmid P., D. Cox, G.K. McMaster, and P. Itin. 1993. In situ hybridization analysis of cytokine, proto-oncogene and tumour suppressor gene expression in psoriasis. Arch. Dermatol. Res. 285:334.
45. Ansel J.C., J.P. Tiesman, J.E. Olerud, J.G. Krueger, J.F. Krane, D.C. Tara, G.D. Shipley, D. Gilbertson, M.L. Usui, and C.E. Hart. 1993. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J. Clin. Invest. 92:671.
46. Krane J.F., D.P. Murphy, A.B. Gottlieb, D.M. Carter, C.E. Hart, and J.G. Krueger. 1991. Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J. Invest. Dermatol. 96:983.